Overview

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Fingolimod Hydrochloride